NASDAQ:NITE Nightstar Therapeutics (NITE) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free NITE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$25.41▼$25.4150-Day Range$25.41▼$25.4152-Week Range$9.59▼$29.55Volume40 shsAverage Volume185,808 shsMarket Capitalization$852.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nightstar Therapeutics alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Nightstar Therapeutics Stock (NASDAQ:NITE)Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.Read More Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide NITE Stock News HeadlinesNovember 12, 2023 | bbc.co.ukThank you for supporting The Big Night InNovember 1, 2023 | usatoday.comBills vs. Giants Sunday Night Football highlights: Buffalo survives for late winApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 14, 2023 | yahoo.comEarly bird vs. night owl — is one really healthier than the other? Here's what research shows.September 14, 2023 | usatoday.comJustin Timberlake, Timbaland curating music for 'Monday Night Football'September 10, 2023 | usatoday.comWho is playing in NFL Sunday Night Football? Here's the complete 2023 SNF scheduleJune 24, 2023 | sfgate.comDisneyland’s first-ever Pride Nite was one of the best nights I’ve ever had in the parkJune 13, 2023 | forbes.comBest Night Guards (Mouth Guards) For Teeth Grinders Of 2023April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 29, 2023 | usatoday.comNFL owners approve flexing of 'Thursday Night Football' gamesMay 16, 2023 | bbc.co.ukDay and nightMay 11, 2023 | bbc.co.ukLast Night tickets informationFebruary 8, 2023 | msn.comThe Night Agent Adaptation From Shield Creator Shawn Ryan Gets Netflix Release Date and Teaser — WatchJanuary 27, 2023 | yahoo.comM. Night Shyamalan’s Knock At The Cabin Has Screened, See What People Are Saying About The Apocalyptic ThrillerOctober 25, 2022 | thetimes.co.ukSyncona puts cash on table for gene therapy group dealAugust 21, 2022 | thestreet.comNightstar Therapeutics plc Sponsored ADR NewsJuly 6, 2022 | investing.comNITE_old Historical DataJanuary 6, 2022 | sg.finance.yahoo.comSensorion appoints Aniz Girach as Independent Board MemberSee More Headlines Receive NITE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2018Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NITE CUSIPN/A CIK1711675 Webwww.nightstartx.com Phone44-20-7062-2777FaxN/AEmployees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.89% Return on Assets-27.65% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book4.31Miscellaneous Outstanding Shares33,540,000Free FloatN/AMarket Cap$852.25 million OptionableNot Optionable Beta2.84 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David Fellows (Age 62)CEO & Director Mr. Senthil Vel Sundaram (Age 41)Chief Financial Officer Dr. Gregory Scott Robinson (Age 60)Chief Scientific Officer Brian LuqueSr. Mang. of Investor RelationsMr. Seokho Bryan Yoon Esq. (Age 40)Gen. Counsel & Sec. Key CompetitorsREGENXBIONASDAQ:RGNXImmaticsNASDAQ:IMTXRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXCabaletta BioNASDAQ:CABAView All Competitors NITE Stock Analysis - Frequently Asked Questions How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.13. What other stocks do shareholders of Nightstar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nightstar Therapeutics investors own include Cronos Group (CRON), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Ligand Pharmaceuticals (LGND), OncoMed Pharmaceuticals (OMED), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Sangamo Therapeutics (SGMO) and Supernus Pharmaceuticals (SUPN). When did Nightstar Therapeutics IPO? Nightstar Therapeutics (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. This page (NASDAQ:NITE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
